Simvastatin increases bone mineral density in hypercholesterolemic postmenopausal women

Metabolism: Clinical and Experimental

Volumn 53, Issue 6, 2004, Pages 744-748

  Lupattelli, Graziana ^a   Scarponi, Anna Maria ^b   Vaudo, Gaetano ^b   Siepi, Donatella ^b   Roscini, Anna Rita ^b   Gemelli, Fabio ^b   Pirro, Matteo ^b   Latini, Roberto A ^b   Sinzinger, Helmut ^b   Marchesi, Simona ^b   Mannarino, Elmo ^b  

^a POLICLINICO MONTELUCE   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

SIMVASTATIN;

ADULT; AGED; ARTICLE; BODY MASS; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIET THERAPY; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIP; HUMAN; HYPERCHOLESTEROLEMIA; LUMBAR SPINE; OSTEOPENIA; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL;

AGED; ALKALINE PHOSPHATASE; ANTICHOLESTEREMIC AGENTS; BONE DENSITY; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DATA INTERPRETATION, STATISTICAL; DENSITOMETRY, X-RAY; FEMALE; FEMUR; FOLLOW-UP STUDIES; HUMANS; HYDROXYPROLINE; HYPERCHOLESTEROLEMIA; MIDDLE AGED; POSTMENOPAUSE; SIMVASTATIN; SPINE; TRIGLYCERIDES;

EID: 3042774550     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2004.01.010     Document Type: Article

References (28)

1. Stein E.A. Management of dyslipidemia in the high-risk patient. Am Heart J. 144:2002;S43-S50
2. La Rosa J.C., He J., Vupputuri S. Effect of statins on risk of coronary disease A meta-analysis of randomized controlled trials. JAMA. 282:1999;2340-2346
3. Crouse J.R. III, Byington R.P., Hoen H.M., et al. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med. 157:1997;1305-1310
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with Simvastatin in 20, 536 high risk individuals A randomised placebo-controlled trial. Lancet. 360:2002;7-22
5. van Beek E., Lowik C., van der Pluijm G., et al. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro A clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res. 14:1999;722-729
6. Mundy G., Garrett R., Harris S., et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 286:1999;1946-1949
7. Meier C.R., Schlienger R.G., Kraenzlin M.E., et al. HMG CoA reductase inhibitors and the risk of fractures. JAMA. 283:2000;3205-3210
8. Wang P.S., Solomon D.H., Mogun H., et al. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA. 283:2000;3211-3216
9. Chan K.A., Andrade S.E., Boles M., et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet. 355:2000;2185-2188
10. Pasco J.A., Kotowicz M.A., Henry M.J., et al. Statin use, bone mineral density, and fracture risk Geelong Osteoporosis Study. Arch Intern Med. 162:2002;537-540
11. van Staa T.P., Wegman S., de Vries F., et al. Use of statins and risk of fractures. JAMA. 285:2001;1850-1855
12. Reid I.R., Hague W., Emberson J., et al. Effect of pravastatin on frequency of fracture in the LIPID study: Secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet. 357:2001;509-512
13. Pedersen T.R., Kjekshus J. 4S Study Group. Statin drugs and the risk of fracture. JAMA. 284:2000;1921-1922
14. Podenphant J., Larsen N.E., Christiansen C. An essay and reliable method for determination of urinary hydroxyproline. Clin Chim Acta. 14:1984;195-198
15. Kanis J.A., Johnell O., Oden A., et al. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone. 27:2000;585-590
16. Adami S., Braga V., Gatti D. Association between bone mineral density and serum lipids in men. JAMA. 286:2001;791-792
17. Chung Y.S., Lee M.D., Lee S.K., et al. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab. 85:2000;1137-1142
18. Edwards C.J., Hart D.J., Spector T.D. Oral statins and increased bone-mineral density in postmenopausal women. Lancet. 355:2000;2218-2219
19. Watanabe S., Fukumoto S., Takeuchi Y., et al. Effects of 1-year treatment with Fluvastatin or Pravastatin on bone. Am J Med. 110:2001;584-587
20. Montagnani A., Gonnelli S., Cepollaro C., et al. Effect of Simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women A 1-year longitudinal study. Bone. 32:2003;427-433
21. Rejinmark L., Buus N.H., Vestergaard P., et al. Statins decrease bone turnover in postmenopausal women A cross sectional study. Eur J Clin Invest. 32:2002;581-589
22. Chan M.H., Mak T.W., Chiu R.W., et al. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. J Clin Endocrinol Metab. 86:2001;4556-4559
23. Stein E.A., Farnier M., Waldstreicher J., et al. Effects of statins on biomarkers of bone metabolism A randomised trial. Nutr Metab Cardiovasc Dis. 11:2001;84-87
24. Goldstein J.L., Brown M.S. Regulation of mevalonate pathway. Nature. 343:1990;425-430
25. Van Aelst L., D'Souza-Schorey C. Rho GTPases and signalling networks. Genes Dev. 11:1997;2295-2322
26. Lane N.E., Rehman Q. Osteoporosis in the rheumatic disease patient. Lupus. 11:2002;675-679
27. Pacifici R., Brown C., Puscheck E., et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci USA. 88:1991;5134-5138
28. Ridker P.M., Rifai N., Pfeffer M.A., et al. The Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 100:1999;230-235